Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539894 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL5134448 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL10674908 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL5540740 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL5544717 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL28601890 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL5544687 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL5539887 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL1728456 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 | |
| SCHEMBL27579193 | 1.00 | DNM1 (0.48) | DNM1OPRM1PLA2G1BPLA2G2ASPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937369-B1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | TOSOH CORP (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | TOSOH CORPORATION (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2937369-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | Tosoh Corporation (JP) | 2015-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | CA2, KCNMB1, BET1 | DNM1 780/4885OPRM1 2250/4885PLA2G1B 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.